Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio

IL-18 modulation has potential for broad applicability in multiple inflammatory diseases Phase 2-ready program complementary to Evommune’s immunology pipeline Phase 1 trial demonstrated good safety and tolerability, favorable pharmacokinetics and target engagement PALO ALTO, Calf., June…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks